Date: 2013-09-13
Type of information: Grant
Company: Karo Bio (Sweden)
Investors: National Multiple Sclerosis Society
Amount: $0,5 million (€0.376 million)
Funding type: grant
Planned used: The funds will be used to develop a novel treatment – ERbeta agonists -- for progressive forms of Multiple Sclerosis (MS).
Others: * On September 13, 2013, Karo Bio AB has been awarded $0,5 million from the National Multiple Sclerosis Society through Fast Forward to develop a novel treatment (ERbeta agonists) for progressive forms of Multiple Sclerosis (MS). The funds will finance the further preclinical development of Karo Bio’s advanced compounds.
Karo Bio’s ERbeta agonist has the potential to slow disease progression in multiple sclerosis as preclinical models show that it protects neurons and restores myelin. Damaged myelin leads to symptoms of illness and disability in MS patients. This intended profile differs dramatically from currently approved MS therapies, which are used for the treatment of relapsing MS and reduce inflammation, but do not restore myelin or directly protect neurons.
Therapeutic area: Neurodegenerative diseases
